Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06719011 · ClinicalTrials.gov registry record · Phase 1

A Study on How NNC0174-1213 Works in People With Overweight or Obesity.

A Phase 1 study of Obesity and Overweight, sponsored by Novo Nordisk A/S.

Recruiting
Registry status
Phase 1
Development phase
177
Enrollment target
2
Study locations

NCT06719011: Recruiting Phase 1 study of Obesity and Overweight, sponsored by Novo Nordisk A/S.

NCT06719011 is a Phase 1 study of Obesity and Overweight that is actively recruiting participants, run by Novo Nordisk A/S. The registered enrollment target is 177 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (78% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06719011, a Phase 1 study of Obesity and Overweight, is actively recruiting participants, sponsored by Novo Nordisk A/S.

RECRUITING
Registry status
Phase 1
Development phase
177 participants
Enrollment target
2
Study locations

Study Summary

This study is testing a new study medicine to treat people living with overweight or obesity. The aim of this study is to see if the medicine is safe, how it works in human body, and what human body does to the study medicine. Participants will either get the new study medicine NNC0174-1213, a study medicine called "cagrilintide" or a placebo (a "dummy medicine" similar to the new study medicine and study medicine but without active ingredients). Which treatment participants will get is decided by chance. The new study medicine and the study medicine are potential new medicines which cannot be prescribed by doctors. This study will last for about a year in total.

Primary Outcome

Number of events

Conditions Studied

Interventions

  • DRUG NNC0174-1213 A
  • DRUG Cagrilintide B
  • DRUG Placebo A (NNC0174 1213 A)

Study Locations (2)

Texas

  • ICON Early Phase Services, LLC - San Antonio

Utah

  • ICON Early Phase Services, LLC - Salt Lake City

Trial Details

FieldValue
Enrollment Target 177 participants
Start Date 2024-12-03
Est. Completion 2026-05-17
Phase Phase 1
Novo Nordisk A/S

431 total trials

What NCT06719011 shows while recruiting

NCT06719011 is an interventional study that assigns participants to a tested intervention. The registered 177 participants enrollment target is mid-sized for trials with a published cap, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (78% lower).

The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 3 interventions - of which NNC0174-1213 A is the first listed.

NCT06719011 reports a single indexed study location in Texas, Utah.

Frequently Asked Questions

What is clinical trial NCT06719011 about?

NCT06719011 is a clinical study titled "A Study on How NNC0174-1213 Works in People With Overweight or Obesity.". This study is testing a new study medicine to treat people living with overweight or obesity. The aim of this study is to see if the medicine is safe, how it works in human body, and what human body does to the study medicine. Participants will either get the new study medicine NNC0174-1213, a study...

What is the current status of trial NCT06719011?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 177 participants. The study started on 2024-12-03. Estimated completion is 2026-05-17.

What conditions does trial NCT06719011 study?

This clinical trial studies the following conditions: Obesity, Overweight.

What interventions are being tested in trial NCT06719011?

The interventions under investigation include: NNC0174-1213 A (DRUG), Cagrilintide B (DRUG), Placebo A (NNC0174 1213 A) (DRUG).

Who is sponsoring clinical trial NCT06719011?

This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06719011 being conducted?

This trial has 2 study locations across Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06719011's enrollment target sits among peer trials

177 347th of 1053 higher than 707 of 1,053 other Obesity trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05491551 · 177 participants · NA

    Alcohol-ROC-Training

  • NCT06108050 · 177 participants · Phase 1

    JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors

  • NCT06575712 · 177 participants · NA

    Coping Skills Training for Symptom Management and Daily Steps (Step Up)

  • NCT06674980 · 177 participants · NA

    Clinical Trial Assessing Human Placental Membrane Products and Standard of Care Versus Standard of Care in Nonhealing DFUs and VLUs

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06719011, the US trial registry maintained by the National Library of Medicine. NCT06719011 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.